| Serum Sarcosine, Variation in Sarcosine-related Genes and Subsequent Risk of Prostate Cancer |
Stella Koutros |
NCI, DCEG, OEEB |
PLCO |
Dec 15, 2009 |
2009-0565 |
| Reconciling Results of PSA Screening Efficacy Using PLCO and ERSPC data: CISNET modeling project |
Angela Mariotto |
NCI, DCCPS, DMB |
PLCO |
Nov 12, 2009 |
2009-0182 |
| New statistical approaches for adjusting seasonal variation in vitamin D concentration measurement, with application in the PLCO nested case-control study of serum vitamin D concentration and prostate cancer risk |
Kai Yu |
NCI, DCEG, BB |
PLCO |
Nov 11, 2009 |
2009-0006 |
| Trichomonosis and prostate cancer risk in the Prostate, Lung, Colorectal & Ovarian Cancer Screening Trial |
Siobhan Sutcliffe |
Washington University |
PLCO |
Nov 9, 2009 |
2009-0556 |
| Telemore length and risk of glioma |
Preetha Rajaraman |
NCI, DCEG, REB |
PLCO |
Nov 9, 2009 |
2009-0557 |
| Modifiable risk factors for benign prostatic hyperplasia |
Siobhan Sutcliffe |
Washington University |
PLCO |
Nov 4, 2009 |
2009-0167 |
| Investigation of Prostate Cancer Risk Factors and Targeted Screening |
Amanda Black |
NCI, DCEG, EBP |
PLCO |
Nov 4, 2009 |
2009-0243 |
| Factors influencing prostate cancer mortality |
David Crawford |
Univeristy of Colorado Health Science Center |
PLCO |
Oct 1, 2009 |
2009-0012 |
| Reproductive history and renal cell carcinoma |
Mark Purdue |
NCI, DCEG, OEEB |
PLCO |
Oct 1, 2009 |
2009-0172 |
| Prospective assessment of thyroid cancer risk and exposure to persistent polyhalogenated aromatic hydrocarbons |
Mary Ward |
NCI, DCEG |
PLCO |
Aug 21, 2009 |
2009-0518 |
| Participant Tracking and Tracing in the PLCO and NLST/LSS Trials |
Pamela Marcus |
NCI, DCP, BRG |
PLCO |
Aug 13, 2009 |
2009-0159 |
| Risk factors for hepatocellular carcinoma in the United States |
Katherine McGlynn |
NCI, DCEG, HREB |
PLCO |
Jul 23, 2009 |
2009-0154 |
| A prospective investigation of the relationship between use of non-steroidal anti-inflammatory drugs (NSAIDs) and risk of head and neck cancers (HNC) and malignant melanomas (MM) |
Amanda Black |
NCI, DCEG, EBP |
PLCO |
Jul 23, 2009 |
2009-0035 |
| Serum Melatonin and Subsequent Risk of Prostate Cancer |
Ann Hsing |
NCI, DCEG, HREB |
PLCO |
Jul 17, 2009 |
2008-0256 |
| Development of a Pancreatic Cancer Risk Prediction Model |
Martin Tammemagi |
Brock University / Henry Ford Health System |
PLCO |
Jul 15, 2009 |
2009-0095 |
| Risk of an Abnormal Suspicious False Positive Screening Exam for Ovarian Cancer in the PLCO Cancer Screening Trial. |
Sarah Nyante |
NCI, DCEG, HREB |
PLCO |
Jul 10, 2009 |
2009-0059 |
| Diet, underlying diseases, reproductive factors and CLL/SLL |
Huei-Ting Tsai |
NCI, DCEG, GEB |
PLCO |
Jun 26, 2009 |
2009-0106 |
| Phase III validation using PLCO specimens of a consensus panel of ovarian cancer biomarkers developed by SPORE/EDRN investigators: Study 4: Validation using PLCO serial specimens of PLCO Ovarian Cance |
Nicole Urban |
Fred Hutchinson Cancer Research Center |
PLCO |
Jun 19, 2009 |
2009-0504 |
| RISK FACTORS FOR INVASIVE BREAST CANCER BY HORMONE RECEPTOR STATUS AND FOR DUCTAL CARCINOMA IN SITU |
Claudine Isaacs |
Georgetown University |
PLCO |
Jun 18, 2009 |
2009-0121 |
| Prospective evaluation of IGF and IL-6 dysregulation and multiple myeloma |
Mark Purdue |
NCI, DCEG, OEEB |
PLCO |
Jun 10, 2009 |
2009-0506 |
